Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
VA Puget Sound Health Care System, Seattle, Washington, United States
Universitaetsklinikum Duesseldorf, Duesseldorf, Germany
University Medical Center Hamburg - Eppendorf, Hamburg, Germany
Johannes Gutenberg University, Mainz, Germany
St. Luke's International Hospital, Tokyo, Japan
National Kyusyu Cancer Center, Fukuoka, Japan
Tokai University Hospital, Kanagawa, Japan
Hospital de la Santa Creu i Sant Pau., Barcelona, Spain
Hospital Durán i Reynals (Bellvitge)., Barcelona, Spain
Hospital General de Alicante., Alicante, Spain
Nantes University hospital, Nantes, France
CHU Caen, Caen, France
CHRU lille, Lille, France
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
Carolina-Levine Children's Hospital, Charlotte, North Carolina, United States
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
Johns Hopkins University/Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.